These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33832088)

  • 61. [Opsoclonus-myoclonus syndrome associated with Mycoplasma pneumoniae infection].
    Chemli J; Ketata S; Dalhoumi A; Ajmi H; Hassayoun S; Fodha I; Boujaafar N; Harbi A
    Arch Pediatr; 2007 Aug; 14(8):1003-6. PubMed ID: 17543509
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Opsoclonus-myoclonus syndrome in children].
    Bembeeva RTs; Petrukhin AS; Bologov AA; Baĭdun LV; Il'ina ES; Samoĭlova MV; Kolpachki LM; Semykina LI; Fedoniuk ID
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(2):4-11. PubMed ID: 18379515
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS).
    Mitchell WG; Wooten AA; O'Neil SH; Rodriguez JG; Cruz RE; Wittern R
    J Child Neurol; 2015 Jul; 30(8):976-82. PubMed ID: 25342308
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Opsoclonus-myoclonus syndrome associated with anti Kelch-like protein-11 antibodies in a young female patient without cancer.
    Fonseca E; Varas R; Godoy-Santín J; Valenzuela R; Sandoval P
    J Neuroimmunol; 2021 Jun; 355():577570. PubMed ID: 33862421
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Opsoclonus myoclonus ataxia syndrome in Israel].
    Blumkin L; Lerman-Sagie T
    Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Opsoclonus-myoclonus syndrome: Clinical characteristics, therapeutic considerations, and prognostic factors in a Spanish paediatric cohort.
    Cantarín-Extremera V; Jiménez-Legido M; Aguilera-Albesa S; Hedrera-Fernández A; Arrabal-Fernández L; Gorría-Redondo N; Martí-Carrera I; Yoldi-Pedtri ME; Sagaseta-De Ilúrdoz M; González-Gutiérrez-Solana L
    Neurologia (Engl Ed); 2023 Mar; 38(2):93-105. PubMed ID: 36396095
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.
    Emamikhah M; Babadi M; Mehrabani M; Jalili M; Pouranian M; Daraie P; Mohaghegh F; Aghavali S; Zaribafian M; Rohani M
    J Neurovirol; 2021 Feb; 27(1):26-34. PubMed ID: 33492608
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Symptomatic myoclonus.
    Borg M
    Neurophysiol Clin; 2006; 36(5-6):309-18. PubMed ID: 17336775
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ophthalmic presentation in the emergency department: a case report of a girl with "shimmering eyes".
    Krivochenitser R; Lemma Y; Wynn B; Jones JS
    J Emerg Med; 2014 Jun; 46(6):e163-5. PubMed ID: 24698510
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.
    Maller B; Peguero E; Tanvetyanon T
    J Immunother; 2018; 41(9):411-412. PubMed ID: 29742520
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung cancer.
    Hassan KA; Kalemkerian GP; Trobe JD
    J Neuroophthalmol; 2008 Mar; 28(1):27-30. PubMed ID: 18347455
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Opsoclonus-myoclonus-ataxia syndrome in an AIDS patient.
    Vale TC; Silva RA; Cunningham MC; Maia DP; Camargos ST; Cardoso F
    Einstein (Sao Paulo); 2013 Dec; 11(4):533-4. PubMed ID: 24488398
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.
    Wilken B; Baumann M; Bien CG; Hero B; Rostasy K; Hanefeld F
    Eur J Paediatr Neurol; 2008 Jan; 12(1):51-5. PubMed ID: 17625938
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Opsoclonus-myoclonus syndrome: a clinicopathological confrontation.
    Baets J; Pals P; Bergmans B; Foncke E; Smets K; Hauman H; Vanderwegen L; Cras P
    Acta Neurol Belg; 2006 Sep; 106(3):142-6. PubMed ID: 17091618
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome.
    Wilbur C; Yea C; Licht C; Irwin MS; Yeh EA
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27776. PubMed ID: 31033188
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Comprehensive treatment of neuroblastoma in children associated with opsoclonus-myoclonus-ataxia syndrome].
    Zhao W; Sun Q; Xie Y; Hua Y; Xiong H; Jia J; Lu X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):540-3. PubMed ID: 25224062
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
    Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
    Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acute transverse myelitis following an opsoclonus-myoclonus syndrome: An unusual presentation.
    Simon T; Cheuret E; Fiedler L; Mengelle C; Baudou E; Deiva K
    Eur J Paediatr Neurol; 2018 Sep; 22(5):878-881. PubMed ID: 29773357
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The opsoclonus–myoclonus syndrome.
    Sahu JK; Prasad K
    Pract Neurol; 2011 Jun; 11(3):160-6. PubMed ID: 21551110
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life.
    Brunklaus A; Pohl K; Zuberi SM; de Sousa C
    Pediatrics; 2011 Aug; 128(2):e388-94. PubMed ID: 21788225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.